Vicriviroc in Combination Therapy with an Optimized Regimen for Treatment‐Experienced Subjects: 48‐Week Results of the VICTOR‐E1 Phase 2 Trial | Zendy

Jamal Suleiman | Zendy; Barry S. Zingman | Zendy; Ricardo Sobhie Diaz | Zendy; José Valdez Madruga | Zendy; Edwin DeJesus | Zendy; Jihad Slim | Zendy; Carmen Mak | Zendy; Erin Lee | Zendy; Michael McCarthy | Zendy; Lisa M. Dunkle | Zendy; Sharon Walmsley | Zendy

Open Access

Vicriviroc in Combination Therapy with an Optimized Regimen for Treatment‐Experienced Subjects: 48‐Week Results of the VICTOR‐E1 Phase 2 Trial

Author(s) -

Jamal Suleiman,

Barry S. Zingman,

Ricardo Sobhie Diaz,

José Valdez Madruga,

Edwin DeJesus,

Jihad Slim,

Carmen Mak,

Erin Lee,

Michael McCarthy,

Lisa M. Dunkle,

Sharon Walmsley

Publication year - 2010

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/650342

Subject(s) - placebo , regimen , medicine , ritonavir , adverse effect , ccr5 receptor antagonist , viral load , clinical endpoint , indinavir , gastroenterology , protease inhibitor (pharmacology) , randomized controlled trial , clinical trial , human immunodeficiency virus (hiv) , immunology , antiretroviral therapy , pathology , alternative medicine , chemokine , receptor , chemokine receptor

Agents that block the CCR5 coreceptor for human immunodeficiency virus (HIV) have demonstrated potent antiretroviral activity. In early clinical studies, the CCR5 antagonist vicriviroc proved to be a safe and effective component of combination antiretroviral therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research